5-MeO-MiPT (Moxy)

5-MeO-MiPT (Moxy) is a tryptamine derivative for neuropsychopharmacology. Purity ≥98% (HPLC). For research purposes only

Here is a standard chemical product description for 5-MeO-MiPT, structured for analytical, forensic, and academic research purposes: **Product Name:** 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine)

**Synonyms:** Moxy; 5-Methoxy-MiPT; 5-Methoxy-N-isopropyl-N-methyltryptamine; 5-methoxy-N-methyl-N-(1-methylethyl)-1H-indole-3-ethanamine **

one gram 5-MeO-MiPT (Moxy) General Description  :
** 5-MeO-MiPT is formally described as N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine. It is a synthetic, psychoactive molecule belonging to the tryptamine class. Structurally, it is closely related to other ring-substituted designer tryptamines such as 5-MeO-DiPT (often referred to as “Foxy”) and 5-MeO-DMT. First detailed in Alexander Shulgin’s seminal text *TiHKAL*, 5-MeO-MiPT is notable for eliciting a blend of entactogenic, stimulating, and psychedelic effects. In analytical, clinical, and forensic toxicology, 5-MeO-MiPT is utilized as a fundamental reference standard. It is essential for the calibration of analytical instrumentation (such as LC-MS/MS, GC-MS, and NMR) and the development of screening methodologies to identify and quantify the substance in seized materials or biological matrices.

**Technical Information (Freebase):** * **CAS
Number:** 96096-55-8 (Freebase) / 83784-06-9 (Hydrochloride salt) *

**Molecular Formula:** C₁₅H₂₂N₂O * **Formula Weight:** 246.35 g/mol * **SMILES:** CC(C)N(C)CCC1=CNC2=C1C=C(C=C2)OC * **InChI Key:** HEDOODBJFVUQMS-UHFFFAOYSA-N *

**Formulation:** Typically supplied as a neat crystalline solid (often formulated as a hydrochloride or fumarate salt to ensure chemical stability, increased water solubility, and accurate dosing) or as a certified reference material solution (e.g., 1 mg/mL in methanol).

**Biological Action:** 5-MeO-MiPT acts predominantly as a potent agonist at central serotonin receptors, exhibiting high binding affinity and efficacy at the 5-HT_1A, 5-HT_2A, and 5-HT_2C subtypes. The robust activation of the 5-HT_2A receptor is highly correlated with its psychedelic properties. In addition to direct receptor agonism, *in vitro* studies indicate that 5-MeO-MiPT potently inhibits the reuptake of the monoamines serotonin and norepinephrine, while leaving dopamine reuptake largely unaffected. This dual mechanism contributes to its unique entactogenic profile. **Regulatory and Safety Information:** * **Intended Use:** This product is intended strictly for use as an analytical reference standard for forensic, toxicological, and academic research purposes.

* **Warning:** **This product is not for human or veterinary use.**

* **Legal Status:** 5-MeO-MiPT is broadly regulated worldwide. In the United Kingdom, it is controlled as a Class A drug under the Misuse of Drugs Act. In the United States, 5-MeO-MiPT is not explicitly scheduled at the federal level; however, due to its close structural and pharmacological similarity to Schedule I substances like 5-MeO-DiPT and 5-MeO-DMT, its manufacturing, distribution, or possession can be prosecuted under the Federal Analogue Act if intended for human consumption. Several U.S. states have scheduled it independently. Procurement may require relevant local licenses. Handling should only occur within professional laboratory environments using appropriate Personal Protective Equipment (PPE) such as safety glasses, chemical-resistant gloves, and a laboratory coat.